Krajina: Indonézia
Jazyk: indonézština
Zdroj: Badan Pengawas Obat dan Makanan RI - Indonesian Food and Drug Supervisory Agency
HEPATITIS A IMMUNOGLOBULIN HUMAN
AVENTIS PHARMA - Indonesia
HEPATITIS A IMMUNOGLOBULIN HUMAN
80 UNIT/0,5 ML
CAIRAN INJEKSI
DUS, 1 PREFILLED SYRINGE @ 0,5 ML
SANOFI PASTEUR - France
2018-03-29
AVAXIM 80 U PEDIATRIC INACTIVATED ADSORBED HEPATITIS A VACCINE COMPOSITION The active ingredient is inactivated** hepatitis A virus (GBM strain)*… ................ 80 ELISA units*** For one 0,5 ml dose * cultured on MRC-5 human diploid cells. ** adsorbed on hydrated aluminium hydroxide (quantity equivalent to 0.15 mg of Al 3+ ). *** antigenic units measured according to the manufacturer’s internal method Excipient with known effect (see section Special warnings and precautions for use ): Phenylalanine… ............................................................................................................ 10 micrograms Per 0.5 mL dose For the full list of excipients, see section List of excipients. PHARMACEUTICAL FORM Suspension for injection in pre-filled syringe. The hepatitis A vaccine (inactivated, adsorbed) is a turbid and whitish suspension. THERAPEUTIC INDICATIONS AVAXIM 80U Pediatric comes in the form of a suspension for injection in a prefilled syringe (0.5 ml) This vaccine is recommended in the prevention of infection induced by hepatitis A virus in children 12 months to 15 years inclusive. This vaccine should be administered in accordance with official recommendations. POSOLOGY AND METHOD OF ADMINISTRATION POSOLOGY _PRIMARY-VACCINATION : _Primary vaccination is achieved with one vaccine dose of 0.5 ml. • _BOOSTER_ One booster dose of 0.5 mL is recommended in order to provide long-term protection. This booster will preferably be administered 6 to 36 months following the primary vaccination dose, but administration will be possible until 7 years after this primary vaccination.. Available data on vaccination with AVAXIM 80 U PEDIATRIC show that after the two doses of the initial vaccination schedule, no other booster vaccination is necessary in immunocompetent individuals, which is in agreement with the official recommendations. It is estimated that anti-VHA antibodies persist several years (beyond 10 years) after the second dose (booster). METHOD OF ADMINISTRATION This vaccine must be adminis Prečítajte si celý dokument